PDF
ePub
Citation
Print
Abstract
Among the patients with hemophilia, 10∼15% have hemophilia B, and 1∼3% of the hemophilia B patients develop inhibitor to factor IX clotting activity. Allergic reactions to concentrates containing factor IX (FIX) are serious complications during the treatment of hemophilia B patients with inhibitor. Although treatment with recombinant activated factor VII (FVIIa) is generally recommended in these patients, it is limited by the agent's short half-life, a lack of experience with its use in this manner and the prohibitive cost. We report here on a case of a 9-year-old boy with severe hemophilia B with inhibitor and he had a history of anaphylaxis to FIX. The patient was successfully treated with a desensitization protocol with escalating doses of FIX in addition to administering premedications.
REFERENCES
1). Warrier I. Inhibitors in hemophilia B. Lee CA, Berntorp EE, Hoots WK, editors. Textbook of hemophilia. 1st ed.MA, USA: Blackwell Publishing;2005. p. 97–100.
2). Warrier I. Factor IX inhibitors and anaphylaxis. Rodriguez EC, Lee CA, editors. Inhibitors in patients with haemophilia. 1st ed.MA, USA: Blackwell Publishing;2002. p. 87–91.
3). Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia. 1998. 4:574–6.
4). Shin SA., Kim YD., Lee H. A case of anaphylactic response to factor IX replacement therapy in hemophilia B patient. Korean J Hematol. 2003. 38:188–90.
5). Katz J. Prevalence of FIX inhibitors among patients with hemophilia B: results of a large North America survey. Haemophilia. 1996. 2:28–31.
6). Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol. 1995. 94(Suppl 1):49–52.
7). Sawamoto Y., Shima M., Yamamoto M, et al. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res. 1996. 83:279–86.
8). Thorland EC., Drost JB., Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia. 1999. 5:101–5.
9). Warrier I., Ewenstein BM., Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997. 19:23–7.
10). Dioun AF., Ewenstein BM., Geha RS., Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol. 1998. 102:113–7.
11). Shibata M., Shima M., Misu H., Okimoto Y., Giddings JC., Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia. 2003. 9:269–71.
12). Curry NS., Misbah SA., Giangrande PL., Keeling DM. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophilia. 2007. 13:328–30.
13). Freiburghaus C., Berntorp E., Ekman M., Gunnarsson M., Kjellberg B., Nilsson IM. Tolerance induction using the Malm treatment model 1982-1995. Haemophilia. 1999. 5:32–9.
14). Chuansumrit A., Moonsup Y., Sirachainan N., Benja-ponpitak S., Suebsangad A., Wongwerawattanakoon P. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul Fibrinolysis. 2008. 19:208–11.
15). Alexander S., Hopewell S., Hunter S., Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol. 2008. 30:93–5.
XML Download